Table 2 Prognostic factors associated overall survival using Cox proportional hazards analysis for patients with cT1 triple-negative breast cancer.
From: Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Characteristics | Total | HR (univariable) | P value | HR (multivariable) | P value |
|---|---|---|---|---|---|
Group | |||||
AC | 5404 (86.5%) | Reference | Reference | ||
NAC | 845 (13.5%) | 1.99 (1.66–2.38) | < 0.001 | 1.46 (1.21–1.76) | < 0.001 |
Age | |||||
< 50 | 1818 (29.1%) | Reference | Reference | ||
≥ 50 | 4431 (70.9%) | 1.09 (0.92–1.28) | 0.306 | 1.27 (1.07–1.50) | 0.006 |
Race | |||||
White | 4663 (74.6%) | Reference | Reference | ||
Black | 1103 (17.7%) | 1.36 (1.14–1.62) | < 0.001 | 1.27 (1.06–1.52) | 0.009 |
Other | 483 (7.7%) | 0.66 (0.47–0.92) | 0.016 | 0.67 (0.48–0.94) | 0.022 |
Marital status | |||||
Married | 4063 (65.0%) | Reference | Reference | ||
Not married | 2186 (35.0%) | 1.34 (1.16–1.56) | < 0.001 | 1.28 (1.10–1.49) | 0.002 |
Histology | |||||
Ductal | 5613 (89.8%) | Reference | Reference | ||
Ductal/lobular | 58 (0.9%) | 2.04 (1.18–3.53) | 0.11 | 1.74 (1.00–3.03) | 0.048 |
Lobular | 34 (0.5%) | 1.04 (0.39–2.79) | 0.933 | 0.96 (0.36–2.57) | 0.930 |
Other | 544 (8.7%) | 0.72 (0.54–0.97) | 0.033 | 0.69 (0.51–0.93) | 0.016 |
Grade | |||||
I | 89 (1.4%) | Reference | Reference | ||
II | 1133 (18.1%) | 2.71 (1.00–7.33) | 0.049 | 2.14 (0.79–5.79) | 0.135 |
III | 4990 (79.9%) | 2.69 (1.00–7.18) | 0.049 | 2.05 (0.77–5.50) | 0.153 |
IV | 37 (0.6%) | 4.46 (1.31–15.23) | 0.017 | 3.51 (1.02–12.03) | 0.046 |
T stage | |||||
T1a | 233 (3.7%) | Reference | Reference | ||
T1b | 1332 (21.3%) | 1.30 (0.74–2.28) | 0.355 | 1.47 (0.84–2.57) | 0.179 |
T1c | 4684 (75.0%) | 2.22 (1.31–3.77) | 0.003 | 2.17 (1.28–3.69) | 0.004 |
N stage | |||||
N0 | 4869 (77.9%) | Reference | Reference | ||
N1 | 1096 (17.5%) | 2.52 (2.14–2.98) | < 0.001 | 2.27 (1.91–2.70) | < 0.001 |
N2–N3 | 284 (4.5%) | 5.88 (4.76–7.26) | < 0.001 | 4.79 (3.81–6.00) | < 0.001 |
Surgery | |||||
BCS | 4099 (65.6%) | Reference | Reference | ||
Mastectomy | 2150 (34.4%) | 1.52 (1.31–1.77) | < 0.001 | 1.38 (1.15–1.64) | < 0.001 |
Radiotherapy | |||||
None/unknown | 2623 (42.0%) | Reference | Reference | ||
Yes | 3626 (58.0%) | 1.03 (0.89–1.20) | 0.687 | 1.10 (0.93–1.31) | 0.275 |
